ReNAgade Therapeutics unveiled Tuesday after closing a $300 million series A, fueled by the promise of RNA technology and a leadership team made up of Moderna vets. And it’s jumping out of the gate with about 100 employees and a new collaboration.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,